

477 W. Horton Rd Bellingham, WA 98226 Phone (360) 933-4892 Fax (360) 933-1197

Patient Name:			_
Date of Birth:	Wt:	Ht:	_
IV Access:			_
Allergies:			

## **Ocrevus Order Form**

<ul> <li>◆ Orders are initiated unless crossed out by provider.</li> <li>□ Check box to initiate order.</li> <li>Please complete this form and fax to (360)933-1197. Call our office for pharmacist recommendations.</li> </ul>			
Diagn •		to therapy initiation required	
Medication Orders:  Ocrevus (ocrelizumab) **Use 0.2 micron filter for administration** □ Initiation: 300 mg/250 ml NS IV on day 1 and 15, then start maintenance dosing every 6 months. Begin infusion at 30 mL/hour; increase by 30 mL/hour every 30 minutes to a maximum rate of 180 mL/hour. □ Maintenance: 600 mg/500 ml NS IV every 6 months. Begin infusion at 100 mL/hour; increase to 200 mL/hour at 15 minutes; increase to 250 mL/hour at 30 minutes; increase to maximum rate of 300 mL/hour at 60 minutes.  • If any serious infusion reactions occur, use slower rate for 600mg dose. Begin infusion at 40 mL/hour; increase by 40 mL/hour every 30 minutes to a maximum rate of 200 At 15 min 200 mL/hr At 30 min 250 mL/hr At 60 min 300 mL/hr    Premedication:			
<ul> <li>Nursing Orders:</li> <li>If no central IV access, RN to insert peripheral IV, rotate site every 72 to 120 hours or as needed.</li> <li>Monitor for infusion reactions during infusions, and observe for at least 1 hour after completion.</li> <li>Dosage adjustment for infusion reactions:         Mild to moderate reactions: Reduce the infusion rate to one-half of the rate at which the reaction occurred; maintain reduced rate for at least 30 minutes. If the reduced rate is tolerated, increase the rate as usual. Severe reactions: Interrupt infusion immediately and administer supportive management as needed. After all symptoms have resolved, restart infusion beginning at a rate one-half of the rate at onset of reaction. If the reduced rate is tolerated, increase the rate as usual. Life-threatening reactions: Immediately stop and permanently discontinue infusion for life-threatening or disabling infusion reaction.     </li> <li>Labs: □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □</li></ul>			
Pr	rescriber Signature	Date	

Form # 350

Please Print Name